Latest News
Our latest research, company updates and industry insight
ClearSky heads to 2022 MDS International Congress in Madrid
The ClearSky Medical Diagnostics team is attending the International Parkinson and Movement Disorder Society (MDS) Congress in Madrid.
SCOR Innovation Podcast: Interview with Professor Smith
ClearSky’s co-founder Professor Stephen Smith discusses disruptive healthcare technologies in neurodegenerative diseases in the latest SCOR Innovation Podcast.
ClearSky attends ADI 2022 London Conference
ClearSky Medical Diagnostics has attended and exhibited at the 35th Global Conference of Alzheimer’s Disease International in June 2022.
Partners Wanted to Accelerate Development of Mild Cognitive Impairment Diagnostic Device
ClearSky Medical Diagnostics has developed an intelligent medical device that can objectively diagnose mild cognitive impairment (MCI), a condition often suggested as an early stage of dementia.
ClearSky’s AI technology supports the novel research of children’s brain health
ClearSky Medical Diagnostics is supporting a new initiative to better understand the development of children’s brains during their early stages of life.
Clearsky Secures Licensing Deal for Commercialisation of PD-Monitor in China
ClearSky Medical Diagnostics and Shanghai Accurature Diagnostics Co Ltd have entered into a strategic cooperation agreement related to PD-Monitor.
Finger Tapping May Differentiate Parkinson’s From Essential Tremor
PD-Monitor could differentiate Parkinson’s from essential tremor without bradykinesia with high accuracy, sensitivity and specificity – according to a study.
ClearSky features at UK–China university consortium
Professor Smith highlighted the work of ClearSky in diagnosing and monitoring Parkinson’s at a UK–China university consortium in November.
Parkinson’s and statins: PD-Monitor in clinical study
ClearSky’s PD-Monitor has been used in a nationwide study to investigate whether statins are effective in slowing the progress of Parkinson’s.
Global recognition for ClearSky Medical Diagnostics
ClearSky Medical Diagnostics is recognised as an ‘up and coming’ company tackling neurodegenerative disease through technology.
LID-Monitor to also ‘manage bradykinesia’ // China study
ClearSky has launched a new study in China to establish introducing bradykinesia as a feature being measured by LID-Monitor.
ClearSky presented at international innovation event MIT REAP
ClearSky’s Professor Stephen Smith hosted a stand at an innovation exchange event in Leeds in January – part of a prestigious international innovation programme that the city of Leeds was chosen to host with Massachusetts Institute of Technology (MIT).